Vitamin B6 Modulates NK Cell Metabolism in Pancreatic Cancer

维生素 B6 调节胰腺癌 NK 细胞代谢

• 批准号: 10568565
• 负责人: Kamiya Mehla
• 金额: $ 39.86万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-05 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10568565
• 关键词: Activated Natural Killer Cell; Adenocarcinoma Cell; Adoptive Transfer; Allogenic; Anabolism; Antitumor Response; Attenuated; Biological Assay; Blood; Cancer Etiology; Carbon; Cell Degranulation; Cell Proliferation; Cell Survival; Cell Therapy; Cell physiology; Cells; Cellular Metabolic Process; Cellular immunotherapy; Cessation of life; Circulation; Coculture Techniques; Coenzyme A; Data; Dependence; Development; Diet; Exclusion; Exhibits; Frequencies; Functional disorder; Glucose; Glutamine; Glycine; Glycogen; Glycogen Phosphorylase; Glycogenolysis Induction; Glycolysis; Growth; Hydroxymethyltransferases; Hypoxia; Immune; Immunotherapy; Impairment; Incidence; Infusion procedures; Interferon Type II; Killer Cells; Kinetics; Knock-out; Kynurenine; Label; Link; Malignant Neoplasms; Malignant neoplasm of pancreas; Mediating; Metabolic; Metabolic Pathway; Metabolism; Modeling; Monitor; Mus; NADP; Natural Killer Cells; Nucleotides; Nutrient; Organoids; Pancreatic Ductal Adenocarcinoma; Pathway interactions; Patients; Phase; Phenotype; Play; Production; Prognostic Factor; Proliferating; Research Personnel; Risk; Role; Serine; Starvation; Supplementation; Survival Rate; T-Lymphocyte; Therapeutic; Therapeutic Studies; Treatment Efficacy; Tryptophan; Tumor Burden; Vitamin B 6 Deficiency; Vitamin B6; Vitamin B6 Metabolism Pathway; attenuation; cancer cell; chemotherapy; cofactor; cytotoxic; exhaust; exhaustion; glycogenolysis; immune function; improved; inhibitor; knock-down; mouse model; neoplastic cell; novel therapeutics; pancreatic cancer cells; pancreatic ductal adenocarcinoma cell; pancreatic ductal adenocarcinoma model; pancreatic neoplasm; patient derived xenograft model; rapid growth; response; standard of care; success; tool; tumor; tumor growth; tumor hypoxia; tumor microenvironment; tumor progression; tumor-immune system interactions; tumorigenesis

Project Summary: The poor survival rates in pancreatic ductal adenocarcinoma patients are in part due to poor response to existing therapies. Thus, there is an urgent need to develop novel therapies. NK cell-based therapies present a promising option because NK cells primarily target tumor cells through direct killing or IFN-gamma production and are not dependent on MHC expression. However, in the tumor microenvironment, NK cells directly compete with tumor cells for nutrients to maintain basal cellular metabolism. Of note, cellular metabolic pathways are closely linked with the effector response of NK cells. Tumor-educated NK cells demonstrate increased glycolysis, which potentiates their cytotoxic activity. However, the complete spectrum of metabolic reprogramming in NK cells is not fully understood. Pancreatic tumors are highly glycolytic. The tumor cells exhibit constant high demand for glucose or glutamine to fuel the anabolic needs and exhaust the essential nutrients in the tumor microenvironment milieu. Nutrient starvation triggers metabolic alterations to support proliferation and the aggressive phenotype of pancreatic tumors. Hence, the pancreatic tumor microenvironment displays nutrient paucity, which restricts the metabolic flux in NK cells. Our preliminary data suggest the scarcity of vitamin B6 in NK-tumor cell co-cultures becomes a limiting factor for the anti-tumor response of NK cells against pancreatic tumor cells and organoids. Furthermore, vitamin B6 paucity and glucose-limitation induce metabolic rewiring in NK cells to sustain glycolysis and downstream metabolic pathways. Of note, tumor progression causes a systemic imbalance of vitamin B6. We observed a significant reduction in systemic vitamin B6 metabolites in PDAC patients. Moreover, we demonstrate that pancreatic tumor cells display increased metabolic flux and dependence on metabolic pathways that are dispensable for NK cells, providing a metabolic vulnerability that can be targeted in combination with vitamin B6 supplementation. Taken together, we posit that pancreatic tumor cells exhaust vitamin B6 in the tumor microenvironment milieu, impacting cellular metabolism and inducing NK cell dysfunction. We will examine (Specific Aim 1) the metabolic pathways that favor tumor cell-mediated vitamin B6 exhaustion in the PDAC TME milieu to sustain tumor cell proliferation under nutrient-limiting conditions. In Specific Aim 2, we will investigate the functional significance of vitamin B6-induced metabolic remodeling in NKs that regulate the anti-tumor response of NK cells in 2D cultures, organoids, and orthotopic mouse models. We will also examine the therapeutic potential of targeting the selective metabolic dependencies of tumor cells, in combination with vitamin B6 supplementation, in the context of nutrient limitation in the tumor microenvironment in orthotopic and patient-derived xenograft models (Specific Aim 3). Overall, our study will investigate the metabolic competition between pancreatic cancer cells and NK cells for understanding the selective metabolic vulnerabilities for developing robust NK-based therapies in the long run.

项目总结：胰腺导管腺癌患者生存率低的部分原因是其预后差